Prism (General Partner) Limited investment portfolio

Hone Bio develops NanoPilot, a lipid‑nanoparticle targeting platform that blocks liver uptake and redirects LNPs to specific extra‑hepatic cell types, enabling precise delivery of therapeutic payloads such as mRNA, gene‑editing constructs and other biologics. It serves pharmaceutical and biotechnology companies that need targeted delivery solutions for vaccines, cell and gene therapies, and related treatments.

Ikarovec Limited develops novel adeno‑associated virus (AAV) gene‑therapy products for ophthalmic indications, including age‑related macular degeneration, diabetic macular edema and ocular hypertension. Its target market is patients with serious, common eye diseases that currently require repeated intravitreal injections.